tradingkey.logo

Precigen Inc

PGEN
4.160USD
-0.030-0.72%
收盘 12/26, 16:00美东报价延迟15分钟
1.47B总市值
亏损市盈率 TTM

Precigen Inc

4.160
-0.030-0.72%

关于 Precigen Inc 公司

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc简介

公司代码PGEN
公司名称Precigen Inc
上市日期Aug 08, 2013
CEOSabzevari (Helen)
员工数量143
证券类型Ordinary Share
年结日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编20876
电话13015569900
网址https://precigen.com/
公司代码PGEN
上市日期Aug 08, 2013
CEOSabzevari (Helen)

Precigen Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+7.39%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+10.16%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
William H. Miller III Living Trust
4.91%
Tang Capital Management, LLC
3.50%
其他
43.24%
持股股东
持股股东
占比
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
William H. Miller III Living Trust
4.91%
Tang Capital Management, LLC
3.50%
其他
43.24%
股东类型
持股股东
占比
Venture Capital
35.04%
Investment Advisor
15.87%
Individual Investor
7.79%
Hedge Fund
7.73%
Investment Advisor/Hedge Fund
6.52%
Corporation
5.84%
Research Firm
1.50%
Pension Fund
0.10%
Bank and Trust
0.05%
其他
19.56%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Third Security, LLC
128.72M
36.47%
+12.39M
+10.65%
Sep 17, 2025
Patient Capital Management, LLC
16.27M
4.61%
-1.10M
-6.35%
Jun 30, 2025
Merck Serono SA
20.65M
5.85%
--
--
Mar 31, 2025
William H. Miller III Living Trust
17.39M
4.93%
+17.39M
--
Jun 26, 2025
BlackRock Institutional Trust Company, N.A.
9.83M
2.79%
+271.44K
+2.84%
Jun 30, 2025
The Vanguard Group, Inc.
9.07M
2.57%
+274.07K
+3.12%
Jun 30, 2025
State Street Investment Management (US)
3.03M
0.86%
-9.03K
-0.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.75M
1.06%
+269.58K
+7.75%
Jun 30, 2025
Iridian Asset Management LLC
4.28M
1.21%
-307.15K
-6.70%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
查看更多
Inspire Small/Mid Cap ESG ETF
占比0.24%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
iShares Micro-Cap ETF
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.12%
State Street SPDR S&P Biotech ETF
占比0.11%
Vanguard US Momentum Factor ETF
占比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.06%
iShares Biotechnology ETF
占比0.05%
iShares Russell 2000 Growth ETF
占比0.03%
ProShares UltraPro Russell2000
占比0.02%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Precigen Inc的前五大股东是谁?

Precigen Inc 的前五大股东如下:
Third Security, LLC持有股份:128.72M,占总股份比例:36.47%。
Patient Capital Management, LLC持有股份:16.27M,占总股份比例:4.61%。
Merck Serono SA持有股份:20.65M,占总股份比例:5.85%。
William H. Miller III Living Trust持有股份:17.39M,占总股份比例:4.93%。
BlackRock Institutional Trust Company, N.A.持有股份:9.83M,占总股份比例:2.79%。

Precigen Inc的前三大股东类型是什么?

Precigen Inc 的前三大股东类型分别是:
Third Security, LLC
Patient Capital Management, LLC
Merck Serono SA

有多少机构持有Precigen Inc(PGEN)的股份?

截至2025Q3,共有286家机构持有Precigen Inc的股份,合计持有的股份价值约为222.21M,占公司总股份的62.96%。与2025Q2相比,机构持股有所增加,增幅为-14.79%。

哪个业务部门对Precigen Inc的收入贡献最大?

在FY2025Q2,Service业务部门对Precigen Inc的收入贡献最大,创收781.00K,占总收入的91.24%。
KeyAI